ProfileGDS5678 / 1436302_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 79% 78% 75% 78% 77% 77% 70% 75% 77% 80% 81% 77% 79% 79% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.4470979
GSM967853U87-EV human glioblastoma xenograft - Control 25.3769978
GSM967854U87-EV human glioblastoma xenograft - Control 35.0303775
GSM967855U87-EV human glioblastoma xenograft - Control 45.5025378
GSM967856U87-EV human glioblastoma xenograft - Control 55.236977
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.0750277
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.3868270
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.9146875
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.1813977
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.7258980
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.7520481
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.313977
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.5150679
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.4965279